Journal of Managed Care & Specialty Pharmacy

Papers
(The H4-Index of Journal of Managed Care & Specialty Pharmacy is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia62
Correction58
Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis47
What is needed to sustain comprehensive medication management? One health plan’s perspectives35
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data28
Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy26
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues19
Associations between chronic active lesions and clinical outcomes in multiple sclerosis: A systematic literature review19
International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments18
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance17
The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder15
Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness14
The effect of early initiation of aripiprazole once-monthly 400 mg on health care resource utilization and health care costs in patients diagnosed with bipolar I disorder: Real-world evidence from US 13
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies13
0.18774795532227